98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.annemergmed.2023.11.003 | DOI Listing |
PLoS Comput Biol
September 2025
Department of Analytical Chemistry, Applied Chemometrics and Molecular Modelling (FABI), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
The serotonin-2A receptor (5-HT2AR) is an interesting target for drug design in the context of antidepressants that might have a rapid onset of action and/or be effective in treatment-resistant cases. The main challenge, however, is that the activation of this receptor can provoke hallucinations. Recent studies have shown that activating the receptor with certain (partial) agonists could potentially give rise to antidepressant effect without hallucinogenic side effects.
View Article and Find Full Text PDFCortex
August 2025
School of Psychology, The University of New South Wales, Sydney, Australia.
Psychedelic therapy is on the rise, as its legalisation is ongoing in multiple countries. Here, we write a note of warning regarding recent reports that people with aphantasia (a blind mind's eye) have acquired visual mental imagery after using psychedelics. While the prospect of gaining, or indeed increasing, visual mental imagery is appealing to many, strong mental imagery has been associated with a range of mental conditions.
View Article and Find Full Text PDFPsychiatry Res
August 2025
Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti-Pescara, Italy; Department of Pharmacy, Pharmacology and Clinical Sciences, University of Hertfordshire, Herts, UK.
Depression is a prevalent and heterogeneous disorder with significant personal and social consequences. The rise of treatment-resistant depression (TRD) challenges traditional approaches and underscores the need for a broader neurobiological perspective. When monoaminergic modulation proves insufficient, clinical guidelines increasingly turn to non-monoaminergic interventions such as neuromodulation techniques and glutamatergic agents, which operate through distinct mechanisms.
View Article and Find Full Text PDFJ Psychopharmacol
August 2025
Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland.
Background: While psychedelics are often claimed to enhance creativity, their precise effects on distinct stages of creative cognition remain poorly understood. This study investigated the acute effects of an ayahuasca-inspired formulation combining N,N-dimethyltryptamine (DMT) and harmine (DMT/HAR), as well as harmine alone (HAR), on micro-level (divergent/convergent thinking) and macro-level (creative process dynamics) creativity.
Methods: In a double-blind, placebo-controlled, within-subject design, 30 healthy male participants completed three sessions (DMT/HAR, HAR, placebo).
J Law Med Ethics
July 2025
McGill University Centre of Genomics and Policy, Montreal, Canada.
Psychedelic treatment with psilocybin is receiving increased attention following clinical trials showing it may help treat end-of-life anxiety, depression, and several other conditions. Despite this, physicians may be reluctant to prescribe psilocybin and carry out psilocybin treatment because of the stigma surrounding psychedelics and the potential for medical malpractice liability. This paper explores whether psilocybin treatment gives rise to a risk of medical malpractice liability for physicians.
View Article and Find Full Text PDF